FUNCTIONAL IMMUNOPHENOTYPING FOR PRECISION THERAPIES IN SEPSIS.

IF 2.7 3区医学 Q2 CRITICAL CARE MEDICINE SHOCK Pub Date : 2025-02-01 Epub Date: 2024-11-20 DOI:10.1097/SHK.0000000000002511

Mahil Rao, Patrick W McGonagill, Scott Brackenridge, Kenneth E Remy, Charles C Caldwell, Richard S Hotchkiss, Lyle L Moldawer, Thomas S Griffith, Vladimir P Badovinac

{"title":"FUNCTIONAL IMMUNOPHENOTYPING FOR PRECISION THERAPIES IN SEPSIS.","authors":"Mahil Rao, Patrick W McGonagill, Scott Brackenridge, Kenneth E Remy, Charles C Caldwell, Richard S Hotchkiss, Lyle L Moldawer, Thomas S Griffith, Vladimir P Badovinac","doi":"10.1097/SHK.0000000000002511","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Sepsis remains a significant cause of morbidity and mortality worldwide. Although many more patients are surviving the acute event, a substantial number enters a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past 50 years, yet novel therapies have been few and far between. Although many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state, or endotype, of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to \"prescreen\" individuals to determine which therapies are most likely to be beneficial.</p>","PeriodicalId":21667,"journal":{"name":"SHOCK","volume":" ","pages":"189-201"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SHOCK","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SHK.0000000000002511","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Sepsis remains a significant cause of morbidity and mortality worldwide. Although many more patients are surviving the acute event, a substantial number enters a state of persistent inflammation and immunosuppression, rendering them more vulnerable to infections. Modulating the host immune response has been a focus of sepsis research for the past 50 years, yet novel therapies have been few and far between. Although many septic patients have similar clinical phenotypes, pathways affected by the septic event differ not only between individuals but also within an individual over the course of illness. These differences ultimately impact overall immune function and response to treatment. Defining the immune state, or endotype, of an individual is critical to understanding which patients will respond to a particular therapy. In this review, we highlight current approaches to define the immune endotype and propose that these technologies may be used to "prescreen" individuals to determine which therapies are most likely to be beneficial.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

功能免疫分型用于败血症的精确治疗。

摘要：脓毒症仍然是世界范围内发病率和死亡率的重要原因。虽然更多的患者在急性事件中幸存下来，但大量患者进入持续炎症和免疫抑制状态，使他们更容易受到感染。在过去的五十年中，调节宿主免疫反应一直是脓毒症研究的焦点，然而新的治疗方法却很少。虽然许多脓毒症患者具有相似的临床表型，但受脓毒症事件影响的途径不仅在个体之间存在差异，而且在个体患病过程中也存在差异。这些差异最终会影响整体免疫功能和对治疗的反应。确定个体的免疫状态（或内源性）对于了解哪些患者会对特定治疗产生反应至关重要。在这篇综述中，我们强调了目前定义免疫内型的方法，并提出这些技术可用于“预筛选”个体，以确定哪种治疗方法最有可能是有益的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

SHOCK 医学-外科

CiteScore

6.20

自引率

3.20%

发文量

199

审稿时长

1 months

期刊介绍： SHOCK®: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches includes studies of novel therapeutic approaches, such as immunomodulation, gene therapy, nutrition, and others. The mission of the Journal is to foster and promote multidisciplinary studies, both experimental and clinical in nature, that critically examine the etiology, mechanisms and novel therapeutics of shock-related pathophysiological conditions. Its purpose is to excel as a vehicle for timely publication in the areas of basic and clinical studies of shock, trauma, sepsis, inflammation, ischemia, and related pathobiological states, with particular emphasis on the biologic mechanisms that determine the response to such injury. Making such information available will ultimately facilitate improved care of the traumatized or septic individual.